Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø

Research at Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø has pioneered B-cell depletion to treat Rheumatoid Arthritis and stimulated the development of B-cell-directed therapies for conditions.

Research at Ïã¸ÛÁùºÏ²ÊÖÐÌØÍø has pioneered B-cell depletion to treat Rheumatoid Arthritis (RA) and stimulated the development of B-cell-directed therapies for other autoimmune rheumatic, haematological and neurological diseases.

Now NICE approved (in 2007 updated for 2011), B-cell depletion (based on rituximab) in RA is as effective as the alternative (anti-TNF drugs) and allows effective treatment for patients unable to gain benefit from anti-TNF drugs.

Rituximab offers cost savings of up to £5,000 per patient and is a more convenient option, being given as an infusion at approximately six monthly intervals. B-cell depletion has also proven to be safe, with many receiving repeated courses of treatment. By mid-2013 an estimated 230,000 patients have been treated with rituximab for RA.
Ìý